The University of Chicago Header Logo

Connection

Clarissa Parker to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Clarissa Parker has written about Lung Neoplasms.
Clarissa Parker
Connection Strength
1.592
Lung Neoplasms
  1. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
    View in: PubMed
    Score: 0.132
  2. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8.
    View in: PubMed
    Score: 0.120
  3. Clinical evaluation and staging of patients who have lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):219-35, v.
    View in: PubMed
    Score: 0.099
  4. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117.
    View in: PubMed
    Score: 0.091
  5. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33.
    View in: PubMed
    Score: 0.088
  6. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
    View in: PubMed
    Score: 0.075
  7. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94.
    View in: PubMed
    Score: 0.075
  8. Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification. Future Oncol. 2011 Jan; 7(1):1-3.
    View in: PubMed
    Score: 0.074
  9. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15.
    View in: PubMed
    Score: 0.069
  10. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008 Feb; 3(2):125-9.
    View in: PubMed
    Score: 0.060
  11. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):145-51.
    View in: PubMed
    Score: 0.060
  12. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep; 5(8):381-7.
    View in: PubMed
    Score: 0.059
  13. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704.
    View in: PubMed
    Score: 0.054
  14. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7.
    View in: PubMed
    Score: 0.054
  15. Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25.
    View in: PubMed
    Score: 0.053
  16. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Mar; 47(3):413-9.
    View in: PubMed
    Score: 0.049
  17. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb; 47(2):253-9.
    View in: PubMed
    Score: 0.049
  18. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 01; 22(21):4341-50.
    View in: PubMed
    Score: 0.048
  19. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
    View in: PubMed
    Score: 0.039
  20. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010 Oct 15; 70(20):7748-54.
    View in: PubMed
    Score: 0.036
  21. The role of induction therapy in the management of resectable non-small cell lung cancer. Cancer Control. 2000 Jan-Feb; 7(1):45-55.
    View in: PubMed
    Score: 0.035
  22. Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. Curr Opin Pulm Med. 1999 Jul; 5(4):194-200.
    View in: PubMed
    Score: 0.033
  23. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007 Sep; 2(9):845-53.
    View in: PubMed
    Score: 0.029
  24. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60.
    View in: PubMed
    Score: 0.026
  25. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2006 Jan; 17(1):104-9.
    View in: PubMed
    Score: 0.026
  26. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004 Dec 01; 22(23):4837-45.
    View in: PubMed
    Score: 0.024
  27. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug 15; 98(4):779-88.
    View in: PubMed
    Score: 0.022
  28. Brain metastases. Curr Treat Options Oncol. 2001 Dec; 2(6):537-47.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.